Dr. Jingfang Ju is Professor at Renaissance School of Medicine, Stony Brook University and is co-founder of Curamir Therapeutics Inc.  Dr. Ju is the inventor of the company’s miRNA-based cancer therapeutic platform technology and holds a number of patents in this field and has over 100 academic publications. In addition to having an NIH/NCI funded translational research laboratory, he was a recipient of the Glaxo Wellcome Oncology Clinical Research Scholar Award. He received his B.S. in Chemical Engineering from Northeastern University in China, Ph.D. in molecular biology and biochemistry from University of Southern California, and post-doctoral fellowship in molecular pharmacology at Yale University.